Loading
Life sciences · Observational Study
ClinicalTrials.gov · November 5, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Observational Study.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Registry record from ClinicalTrials.gov (NCT07613151). This is a study registration, not published results. Lead sponsor: Istituto Oncologico Veneto IRCCS. Recruitment status: RECRUITING. Study type: OBSERVATIONAL. Enrollment: 250 participants (ESTIMATED). Conditions: Lobular Breast Carcinoma. Interventions: PROCEDURE: Upfront Breast Surgery; RADIATION: Adjuvant Radiotherapy; DRUG: Endocrine Therapy; DRUG: Chemotherapy. Primary outcome measures: Invasive disease-free survival (iDFS) , Through study completion, an average of 5 years. Brief summary: The NAPOLI Study is a retrospective multicenter observational study designed to characterize hormone receptor-negative/low invasive lobular carcinoma of the breast. The study will collect real-world clinicopathological, molecular, therapeutic and outcome data from patients diagnosed and treated at participating centers. The aim is to describe the clinical behavior, pathological features, receptor profile, treatments received and oncologic outcomes of this rare breast cancer subtype.